Quantcast

Latest Ranibizumab Stories

2011-05-16 07:36:00

SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT). AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse(TM) survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news. Amy Tsang, a...

2011-04-28 21:14:23

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD. The report, from the Comparison of AMD Treatments Trials (CATT), was published online today in the New England Journal of Medicine. CATT is funded by the National Eye Institute...

2011-04-28 11:48:00

CLEVELAND, April 28, 2011 /PRNewswire/ -- A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD). The results are from the landmark "Comparison of AMD Treatments Trials" (CATT) study, a pioneering comparative effectiveness trial made possible through funding by the National Eye...

2011-03-21 03:09:00

LONDON, March 21, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology...

2011-03-18 17:12:00

FREMONT, Calif., March 18, 2011 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655...

2011-03-07 06:00:00

INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million, as compared with actual results of $62 million for the first quarter of 2010, an expected 34 percent year-over-year increase. Included in first quarter revenue guidance is the $10 million settlement received from UCB Pharma S.A. (UCB) in January 2010 resolving all legal disputes between the...

2011-02-28 06:00:00

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has entered into a definitive settlement agreement with Novartis that resolves all disputes between them. Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in Nevada court, which also includes Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd (Roche) as defendants. Novartis agreed to withdraw its opposition appeal in the...

2011-02-22 07:00:00

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months. Regeneron's submission includes a...

2011-02-17 06:00:00

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones. "2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein...

2011-02-09 08:00:00

TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will webcast an investor briefing on Sunday, February 13 from 9 a.m. to 10:30 a.m. Eastern Time. At the investor briefing, principal investigators from the VEGF Trap-Eye clinical studies will recap presentations from the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting being held in Miami, Florida on Saturday, February 12. The...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related